Three Houston-based health tech companies were announced to have joined the 2022 cohort of MedTech Innovator. Photo via Getty Images

Three Houston-based medtech startups are getting a big boost from a medtech accelerator.

The startups — Ad Vital, Corveus Medical, and CorInnova — have been chosen from this year’s cohort for MedTech Innovator, an international accelerator that helps companies that created health care technology. In all, 55 startups are involved in this year’s four-month accelerator program.

Ad Vital and Corveus Medical also are participating in MedTech Innovator’s corporate mentorship program, while CorInnova is one of five startups picked for the pediatric accelerator track.

MedTech Innovator’s 10th annual program kicked off in mid-June at the MedTech Innovator Summit in Mountain View, California. Leaders from each of the 50 startups attended networking events and workshops with MedTech Innovator partners and other industry professionals. Members of this year’s cohort also were featured June 17 at the WSGR Medical Device Conference in San Francisco.

Only 5 percent of applicants were accepted for this year’s accelerator program. Earlier this year, MedTech Innovator held in-person pitch events in five cities, including Houston.

At the conclusion of the 2022 program, MedTech Innovator will award $500,000 in cash and in-kind prizes at this October’s MedTech Conference in Boston. The grand prize is $350,000.

“Over the past nine years, MedTech Innovator has established a unique track record of identifying and supporting leading startups, with 95 percent of our graduates either still in business or having been acquired,” Paul Grand, CEO of MedTech Innovator, says in a news release.

Here’s an overview of what Ad Vital, Corveus Medical, and CorInnova do:

  • Ad Vital’s app helps medical practices through sales, marketing, and operations. For instance, the app automatically organizes sales campaigns aimed at converting customer leads via text messages, emails, and Facebook messages.
  • Corveus Medical’s catheter device is designed to prevent heart failure. More than 6 million American adults experience heart failure. The company is also among five selected to pitch in October for a competition from the National Capital Consortium for Pediatric Device Innovation.
  • CorInnova’s minimally invasive device is engineered to treat congestive heart failure, particularly infants. Each year, about 10,000 babies born in the U.S. have critical heart defects that often require surgery or other procedures.
Houston's medical innovation community congregated to discuss breakthrough innovations in health care. Photo via Getty Images

Houston organizations announce 10 most promising life science startups

future of health care

What startups are creating the future of health care? A Houston conference this week gathered to discuss.

The 10th annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship engaged thought leadership within the life science community with panels, discussions, and more. Additionally, 49 companies pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Austin-based Dynamic Light won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The software company integrates with microscope or robotic systems to provide better visuals to surgeons and health care providers and reduce medical errors, radiation and costs. The award was presented by Ann Tanabe, CEO of BioHouston.

The event also named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Ares Immunotherapy

Photo via Getty Images

Based in Cartersville, Georgia, Ares Immunotherapy uses a unique subset of T-cells for the treatment of solid tumors. According to the company, it is is preparing for a first in man trial in mesothelioma in 2023.

Corveus Medical

Photo courtesy of TMC

Houston-based Corveus Medical, which was formerly known as Caridian Medical, is a part of TMC's Biodesign program. The company was founded by Ishan Kamat, COO, and Tyler Melton, CEO.

"We are developing a novel, catheter-based device that performs a targeted sympathetic nerve ablation to treat heart failure," according to the company. "Our solution leverages the body’s natural mechanisms to bring fluid levels back to normal, giving physicians an effective treatment option, reducing costs for hospitals, and improving quality of life for the patient."

Drusolv Therapeutics

Photo via Pexels

Drusolv Therapeutics, based in Philadelphia, Pennsylvania, was founded out of Harvard University and been validated in a proof-of-concept clinical trial. The company's product, a novel reformulation of atorvastatin, is targeting age-related macular degeneration, or AMD, a serious eye disease. According to the company, it's a $4 billion a year, unmet need.

EMPIRI

Photo via jlabs.jnjinnovation.com

Houston-based EMPIRI is an early-stage biotechnology company currently focusing on precision oncology and utilizing automation for personal diagnosis. The company works out of JLABS @ TMC.

"Our proprietary 3D tissue culture method, E-slices, enables personalized drug response measurements from intact patient tissues," per the company. "E-slice has been clinically validated to accurately predict individual cancer patient responses to chemotherapies, targeted therapies, a immunotherapies."

Lapovations

Photo via Getty Images

Based in Fayetteville, Arkansas, Lapovations is working on technologies that improve laparoscopy.

"Our flagship product AbGrab is a single-use device that uses suction to lift the abdominal wall prior to closed insertion entry," according to the company. "Manually lifting can be difficult and unreliable, especially with obese patients or for clinicians with small hands."

Maxwell Biosciences

Photo by Chokniti Khongchum from Pexels

Austin-based Maxwell Biosciences is creating anti-infectives that inactivate a broad spectrum of viruses. The company's product, CLAROMERS, has seen success in its preclinical animal studies, as well as lab-grown human tissues. Maxwell is fueled by over $30 million in non-dilutive and government funding (e.g. DARPA, NIH, NIAID).

NeuraStasis

Image via neurastasis.com

Doctors have to respond quickly when treating ischemic stroke patients, and Houston-based NeuraStasis is working on a way to give them more time. Each minute a patient is waiting, irreparable damage is being done. The company's noninvasive solution uses electrical neurostimulation to preserve brain functionality. NeuraStasis is based in JLABS @ TMC.

Vena Medical

Image via venamed.ca

Canada medical device company Vena Medical is working on the "world's smallest camera" that is able to record inside veins and arteries to help physicians treat stroke.

Vivifi Medical

Photo courtesy of TMC

Houston-based Vivifi Medical, a Texas Medical Center Innovation company, is working to improve the quality of life of patients with Male Infertility and benign prostatic hyperplasia — 12 million men in the United States alone — by ending recurrency via suture-less laparoscopic technology.

XN Health

Image via xn-health.com

XN Health, based in Houston, has developed a novel approach to phrenic nerve stimulation to treat progression of ventilator induced diaphragm disfunction to help wean patients off the ventilator faster. The technology should speed up patient liberation times, shortening ICU stay, improve healthcare outcomes, and reduce health care costs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston leaders form coalition to boost Texas power grid with new tech

a better grid

A Houston-based coalition that launched this month aims to educate Texas officials about technology designed to shore up the state’s power grid.

The public-private Texas Reliability Coalition says it will promote utility-scale microgrid technology geared toward strengthening the resilience and reliability of the Texas power grid, particularly during extreme weather.

A utility-operated microgrid is a group of interconnected power loads and distributed energy sources that can operate in tandem with or apart from regular power grids, such as the grid run by the Electric Reliability Council of Texas (ERCOT). Legislation passed in 2023 enables the use of utility-scale microgrid technology in Texas’ deregulated energy market, according to the coalition.

John Elder, executive director of the coalition, says that with the legal framework now in place, the Public Utility Commission of Texas and ERCOT need to create rules to establish the Texas marketplace for microgrid technology. The goal, he says, is to “take the Texas grid from good to great” by installing microgrid technology, improving the infrastructure, and strengthening the system — all targeted toward meeting power needs during extreme weather and amid growing demand.

Houston-based CenterPoint Energy will test the utility-scale microgrid technology being promoted by the coalition. In a January 31 filing with the Public Utility Commission, CenterPoint says microgrid technology will be featured in a $36.5 million pilot program that’ll set up an estimated three to five microgrids in the company’s service area. The pilot program is slated to last from 2026 to 2028.

In the public affairs arena, five Houston executives are leading the new reliability commission’s microgrid initiative.

Elder, one of the coalition’s founding members, is president and CEO of Houston-based Acclaim Energy. Other founders include Ember Real Estate Investment & Development, Park Eight Development, and PowerSecure. Ember and Park Eight are based in Houston. Durham, North Carolina-based PowerSecure, which produces microgrid technology, is a subsidiary of energy provider Southern Co.

Aside from Elder, members of the coalition’s board are:

  • Stewart Black, board secretary of the coalition and vice president of Acclaim Energy’s midstream division
  • Todd Burrer, president of municipal utility districts at Inframark
  • Harry Masterson, managing principal of Ember
  • Martin Narendorf, former vice president at CenterPoint Energy

———

This article originally appeared on our sister site, EnergyCapital.

This Houston neighbor is the fastest growing wealthy suburb in America

By The Numbers

The Houston-area city of Fulshear is booming like nowhere else: It's now the No. 1 fast-growing affluent suburb in the country.

Fulshear's No. 1 status was unveiled in a new GoBankingRates' study that ranked the "30 Fastest Growing Wealthy Suburbs in America" for 2025. The report examined population changes from 2018 to 2023 among cities and towns in major U.S. metro areas with populations between 25,000 and 100,000 residents. Median household income, average home value, and a "livability score" were also calculated for each locale.

Fulshear, located 34 miles west of downtown Houston, experienced the most dramatic population increase out of all 30 cities in the report. Though the suburb only has an estimated population of 42,616 residents, that number has skyrocketed 237 percent during the five-year period.

A Fulshear resident's median income is $178,398 annually, and the average value of a home in the city comes out to $521,157, the report additionally found.

Fulshear was the second fastest growing city in America in 2023. The city's growth is further reflected by the number of new apartments that were built in the area in 2024.

Texas is tops
Texas cities took the top three fastest growing U.S. suburbs for 2025, with Dallas-area cities of Celina (No. 2) and Prosper (No. 3) experiencing wildly different (yet still sky high) population changes. Celina's population ballooned 190 percent to 43,317 residents, while Prosper's grew 81 percent to an estimated 41,660 people.

Other Texas cities that earned spots in the report include Flower Mound (No. 19), Southlake (No. 27), University Park (No. 28) and Colleyville (No. 29), all in the Dallas-Fort Worth area.

"The old adage that everything is bigger in Texas is true, considering the number of Lone Star State suburbs that are quickly growing in population and overall wealth," the report's author wrote.

The top 10 fastest growing wealthy suburbs in America are:

  • No. 1 – Fulshear, Texas
  • No. 2 – Celina, Texas
  • No. 3 – Prosper, Texas
  • No. 4 – Erie, Colorado
  • No. 5 – Clarksburg, Maryland
  • No. 6 – Zionsville, Indiana
  • No. 7 – Redmond, Washington
  • No. 8 – Dublin, California
  • No. 9 – Parkland, Florida
  • No. 10 – Eastvale, California
---

This story originally appeared on our sister site CultureMap.com.

Rice research breakthrough paves the way for advanced disease therapies

study up

Bioengineers at Rice University have developed a “new construction kit” for building custom sense-and-respond circuits in human cells, representing a major breakthrough in the field of synthetic biology, which could "revolutionize" autoimmune disease and cancer therapeutics.

In a study published in the journal Science, the team focused on phosphorylation, a cellular process in the body in which a phosphate group is added to a protein, signaling a response. In multicellular organisms, phosphorylation-based signaling can involve a multistage, or a cascading-like effect. Rice’s team set out to show that each cycle in a cascade can be treated as an elementary unit, meaning that they can be reassembled in new configurations to form entirely novel pathways linking cellular inputs and outputs.

Previous research on using phosphorylation-based signaling for therapeutic purposes has focused on re-engineering pathways.

“This opens up the signaling circuit design space dramatically,” Caleb Bashor, assistant professor of bioengineering and biosciences and corresponding author on the study, said in a news release. “It turns out, phosphorylation cycles are not just interconnected but interconnectable … Our design strategy enabled us to engineer synthetic phosphorylation circuits that are not only highly tunable but that can also function in parallel with cells’ own processes without impacting their viability or growth rate.”

Bashor is the deputy director for the Rice Synthetic Biology Institute, which launched last year.

The Rice lab's sense-and-respond cellular circuit design is also innovative because phosphorylation occurs rapidly. Thus, the new circuits could potentially be programmed to respond to physiological events in minutes, compared to other methods, which take hours to activate.

Rice’s team successfully tested the circuits for sensitivity and their ability to respond to external signals, such as inflammatory issues. The researchers then used the framework to engineer a cellular circuit that can detect certain factors, control autoimmune flare-ups and reduce immunotherapy-associated toxicity.

“This work brings us a whole lot closer to being able to build ‘smart cells’ that can detect signs of disease and immediately release customizable treatments in response,” Xiaoyu Yang, a graduate student in the Systems, Synthetic and Physical Biology Ph.D. program at Rice who is the lead author on the study, said in a news release.

Ajo-Franklin, a professor of biosciences, bioengineering, chemical and biomolecular engineering and a Cancer Prevention and Research Institute of Texas Scholar, added “the Bashor lab’s work vaults us forward to a new frontier — controlling mammalian cells’ immediate response to change.”